Lev Ginzburg, MD
Gastroenterology · New Hyde Park, NYNPI 1528086212
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 52.4% of the total. Reporting peaked in 2023 at $3,728 and has fallen 96.8% since, to $121 in 2024.
Across 263 payments — averaging $31.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- AbbVie$885
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$656
- Pfizer$536
- Johnson & Johnson$400
- Merck$184
- plus $1K from 17 others
Across 236 payments — averaging $2622.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$529K
- Eli Lilly$37K
- Boehringer Ingelheim$32K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Janssen Research & Development, LLC$9K
- Boehringer Ingelheim RCV GmbH & Co KG$2K
- plus $34 from 1 others
What the payments were for
- Consulting fees$3,74346%
- Speaking & faculty fees$1252%
- Food & beverage$4,35053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $4,308 |
| AbbVie | 57 | $885 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $656 |
| Pfizer | 29 | $536 |
| Johnson & Johnson | 23 | $400 |
| Merck | 12 | $184 |
| Bristol Myers Squibb | 10 | $176 |
| Intercept Pharmaceuticals, Inc. | 10 | $158 |
| Ferring Pharmaceuticals Inc. | 10 | $156 |
| UCB, Inc. | 7 | $140 |
| Redhill Biopharma Inc. | 9 | $132 |
| Daiichi Sankyo Inc. | 6 | $118 |
| Ironwood Pharmaceuticals, Inc | 4 | $66 |
| Gilead | 4 | $62 |
| Ardelyx, Inc. | 2 | $49 |
| Shire North American Group Inc | 2 | $39 |
| Sanofi | 2 | $37 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Vivus LLC | 2 | $30 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Concordia Pharmaceuticals Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
| QOL Medical, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,219 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 68 | $1,734,782 |
| GattexTeduglutide | 11 | $452,215 |
| Humira(Cf) PenAdalimumab | 19 | $345,836 |
| CreonLipase/Protease/Amylase | 61 | $93,214 |
| XifaxanRifaximin | 34 | $92,560 |
| Mesalamine | 89 | $54,187 |
| Aprepitant | 16 | $53,696 |
| LinzessLinaclotide | 62 | $44,463 |
| ZenpepLipase/Protease/Amylase | 27 | $34,458 |
| RelistorMethylnaltrexone Bromide | 12 | $28,008 |
| Dexlansoprazole DrDexlansoprazole | 64 | $18,325 |
| MotegrityPrucalopride Succinate | 20 | $16,753 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 222 | $13,604 |
| DexilantDexlansoprazole | 27 | $13,216 |
| ProtonixPantoprazole Sodium | 19 | $11,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $400 | $1,734,78268 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex, Motegrity, Dexilant | $4,308 | $482,18458 claims |
| AbbVieCreon, Linzess | $885 | $137,677123 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Apriso | $656 | $131,69562 claims |
| PfizerProtonix | $536 | $11,81419 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $156 | $4,24225 claims |
| Braintree Laboratories, Inc.Sutab | $30 | $2,01713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New Hyde Park
- Ian StorchNew Hyde Park$166K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.